We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

POCT Market Reaches USD 18 Billion in 2016

By LabMedica International staff writers
Posted on 10 Mar 2017
Print article
Sales of point of care (POC) diagnostic testing, both professional testing and self-testing, reached USD 18.4 billion in 2016, driven by emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices that aim to provide expedited diagnosis where the patient is seen or in the patient’s home. These new technologies are allowing POC devices to generate quantitative lab-quality test results and transfer them automatically to an information system, a remote caregiver service for consultation or an electronic medical record.

These are the latest findings of Kalorama Information, an independent medical market research firm.

Over the past 10 years, POC test devices have contributed significantly to the growth of the overall diagnostics market. A large number of diagnostic manufacturers have focused on obtaining CLIA waiver status for their POC devices and CE Mark for POC or self-use. Additionally, more decentralized test venues are investing in non-waived rapid tests and instruments POC testing is expected to play an even more significant role in diagnosis and monitoring patient care.

Currently, molecular POC tests in physician office are available for respiratory infections and more. The market for POC molecular test devices will be driven by their ability to provide precise answers for time sensitive tests, such as sexually transmissible diseases and other infections.

However, with lab budgets across the world being cut for test send-outs, there is a lack of trained technologists to run molecular tests in their present configuration. The new pharma model will resolve this by tailoring therapy to the individual’s particular disease physiology, often determined by the results of a diagnostic test. As a result, more tests – molecular and immunoassays – are expected to come to market, with their adoption being based on performance data, contribution to patient outcome and cost/benefit analysis.

An aging population across the world will provide sufficient room for growth of the POC testing market in the developing as well as developed countries. The evolving POC testing market comprises large and small companies involved in development and/or marketing. The key companies are likely to maintain their leading position in the market through continued product innovation and strategic alliances and mergers.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.